ABSTRACT
OBJECTIVE: For the majority of people with acute sore throat, over-the-counter treatments represent the primary option for symptomatic relief. This study evaluated the in vitro bactericidal activity of lozenges containing the antiseptic hexylresorcinol against five bacteria associated with acute sore throat: Staphylococcus aureus, Streptococcus pyogenes, Moraxella catarrhalis, Haemophilus influenzae and Fusobacterium necrophorum. RESULTS: Hexylresorcinol 2.4 mg lozenges were dissolved into 5 mL of artificial saliva medium. Inoculum cultures were prepared in triplicate for each test organism to give an approximate population of 108 colony-forming units (cfu)/mL. Bactericidal activity was measured by log reduction in cfu. Greater than 3log10 reductions in cfu were observed at 1 min after dissolved hexylresorcinol lozenges were added to S. aureus (log10 reduction cfu/mL ± standard deviation, 3.3 ± 0.2), M. catarrhalis (4.7 ± 0.4), H. influenzae (5.8 ± 0.4) and F. necrophorum (4.5 ± 0.2) and by 5 min for S. pyogenes (4.3 ± 0.4). Hexylresorcinol lozenges achieved a > 99.9% reduction in cfu against all tested organisms within 5 min, which is consistent with the duration for a lozenge to dissolve in the mouth. In conclusion, in vitro data indicate that hexylresorcinol lozenges offer rapid bactericidal activity against organisms implicated in acute sore throat.
Subject(s)
Bacterial Infections/drug therapy , Common Cold/drug therapy , Hexylresorcinol/therapeutic use , Oropharynx/drug effects , Administration, Oral , Anti-Infective Agents, Local/administration & dosage , Anti-Infective Agents, Local/therapeutic use , Bacterial Infections/microbiology , Bacterial Load/drug effects , Common Cold/microbiology , Fusobacterium necrophorum/drug effects , Fusobacterium necrophorum/physiology , Haemophilus influenzae/drug effects , Haemophilus influenzae/physiology , Hexylresorcinol/administration & dosage , Humans , Microbial Sensitivity Tests , Moraxella catarrhalis/drug effects , Moraxella catarrhalis/physiology , Oropharynx/microbiology , Staphylococcus aureus/drug effects , Staphylococcus aureus/physiology , Streptococcus pyogenes/drug effects , Streptococcus pyogenes/physiology , Time FactorsABSTRACT
OBJECTIVE: There is no pharmacological treatment for oropharyngeal dysphagia (OD). The aim of this study was to compare the therapeutic effect of stimulation of oropharyngeal transient receptor potential vanilloid type 1 (TRPV1) with that of thickeners in older patients with OD. DESIGN: A clinical videofluoroscopic non-randomised study was performed to assess the signs of safety and efficacy of swallow and the swallow response in (1) 33 patients with OD (75.94 ± 1.88 years) while swallowing 5, 10 and 20 ml of liquid (20.4 mPa.s), nectar (274.4 mPa.s), and pudding (3930 mPa.s) boluses; (2) 33 patients with OD (73.94 ± 2.23 years) while swallowing 5, 10 and 20 ml nectar boluses, and two series of nectar boluses with 150 µM capsaicinoids and (3) 8 older controls (76.88 ± 1.51 years) while swallowing 5, 10 and 20 ml nectar boluses. RESULTS: Increasing bolus viscosity reduced the prevalence of laryngeal penetrations by 72.03% (p < 0.05), increased pharyngeal residue by 41.37% (p < 0.05), delayed the upper esophageal sphincter opening time and the larynx movement and did not affect the laryngeal vestibule closure time and maximal hyoid displacement. Treatment with capsaicinoids reduced both, penetrations by 50.% (p < 0.05) and pharyngeal residue by 50.% (p < 0.05), and shortened the time of laryngeal vestibule closure (p < 0.001), upper esophageal sphincter opening (p < 0.05) and maximal hyoid and laryngeal displacement. CONCLUSION: Stimulation of TRPV1 by capsaicinoids strongly improved safety and efficacy of swallow and shortened the swallow response in older patients with OD. Stimulation of TRPV1 might become a pharmacologic strategy to treat OD.
Subject(s)
Capsaicin/administration & dosage , Deglutition Disorders , Deglutition/drug effects , Oropharynx , Starch/therapeutic use , TRPV Cation Channels/metabolism , Aged , Chromatography, Liquid/methods , Deglutition Disorders/drug therapy , Deglutition Disorders/etiology , Deglutition Disorders/physiopathology , Drug Monitoring , Female , Fluoroscopy/methods , Food Additives/therapeutic use , Geriatric Assessment/methods , Humans , Male , Oropharynx/drug effects , Oropharynx/metabolism , Oropharynx/physiopathology , Sensory System Agents/administration & dosage , Treatment Outcome , Video RecordingABSTRACT
The olive oil phenolic oleocanthal is a natural nonsteroidal anti-inflammatory compound that irritates the oral pharynx in a dose-dependent manner. It has been proposed that the biological activity of oleocanthal is partially responsible for the beneficial health effects of the Mediterranean diet. Virgin olive oil containing oleocanthal is often added as an ingredient in a number of cooked dishes, and therefore it is of great importance to understand how best to preserve the putative health-promoting benefits of this compound, as olive oil phenolics are subject to degradation upon heating in general. One extra virgin olive oil containing 53.9 mg/kg oleocanthal was heated at various temperatures (100, 170, and 240 degrees C) for set time periods (0, 1, 5, 20, 60, and 90 min). Oleocanthal concentrations were quantified using HPLC, and its biological activity was determined with a taste bioassay measuring the intensity of throat irritation. Results demonstrated that oleocanthal was heat stable compared with other olive oil phenolics, with a maximum loss of 16% as determined by HPLC analysis. However, there was a significant decrease of up to 31% (p < 0.05) in the biological activity of oleocanthal as determined by the taste bioassay. Although there was minimal degradation of oleocanthal concentration, there was a significant decrease in the biological activity of oleocanthal upon extended heating time, indicating a possible loss of the putative health -benefiting properties of oleocanthal. Alternatively, the difference in the concentration and biological activity of oleocanthal after heat treatment could be a result of an oleocanthal antagonist forming, decreasing or masking the biological activity of oleocanthal.
Subject(s)
Aldehydes/analysis , Aldehydes/pharmacology , Anti-Inflammatory Agents/pharmacology , Hot Temperature , Phenols/analysis , Phenols/pharmacology , Plant Oils/chemistry , Adult , Chromatography, High Pressure Liquid , Cyclopentane Monoterpenes , Drug Stability , Female , Food Handling/methods , Health Promotion , Humans , Male , Olive Oil , Oropharynx/drug effects , TasteABSTRACT
The therapeutic efficacy of CS-758, a novel triazole, was evaluated against experimental murine oropharyngeal candidiasis induced by Candida albicans with various susceptibilities to fluconazole. Against infections induced by strains with various susceptibilities to fluconazole, the efficacy of fluconazole was strongly correlated with the MIC of fluconazole, as measured by the NCCLS method, and agreed with the NCCLS interpretive breakpoints, suggesting that the efficacies of new drugs could be predicted by using this model. The results of the fungal burden study corresponded with the results of the histopathological study. CS-758 exhibited potent in vitro activity (MICs, 0.004 to 0.06 micro g/ml) against the strains used in this murine model including fluconazole-susceptible dose-dependent and fluconazole-resistant strains (fluconazole MICs, 16 to 64 micro g/ml). CS-758 exhibited excellent efficacy against the infections induced by all the strains including a fluconazole-resistant strain, and the reductions in viable cell counts were significant at 10 and 50 mg/kg of body weight/dose. Fluconazole was not effective even at 50 mg/kg/dose against infections induced by a fluconazole-resistant strain (fluconazole MIC, 64 micro g/ml). These results suggest that CS-758 is a promising compound for the treatment of oropharyngeal candidiasis including fluconazole-refractory infections.
Subject(s)
Antifungal Agents/pharmacology , Candidiasis/drug therapy , Fluconazole/pharmacology , Triazoles/therapeutic use , Animals , Candidiasis/pathology , Drug Resistance, Fungal , Male , Mice , Microbial Sensitivity Tests , Oropharynx/drug effects , Oropharynx/microbiology , Tongue/pathologyABSTRACT
This paper describes a technique that uses a well-defined human airway replica and gamma counting as a standard method for evaluating and comparing the performance of medical inhalers and spacers. High-fidelity replicas reproduced as needed from master casts made from human cadavers include the oropharyngeal cavity, larynx, trachea, and five to nine generations of bronchi. Deposition in the small airways and alveoli region of the cast is simulated by material that passes through the upstream airways and is collected on foam filters. Deposition patterns in the respiratory tract replica were obtained by using radiolabel in the medical inhaler and by gamma scintigraphy. This technique was used to determine respiratory deposition patterns of salbutamol in a pressurized metered dose inhaler (pMDI) with chlorofluorocarbon (CFC, in-house formulation) and HFA-134 formulations (Proventil hydrofluoroalkane [HFA]). At an inspiration flow of 30 L/min, patterns in the salbutamol/CFC formula showed a high deposition in the oropharyngeal airway (78%) and a 16% deposition in the lung, similar to in vivo measurements reported in the literature. However, the salbutamol/HFA formula showed lower oral deposition (56%) but higher lung deposition (24%). The difference in the oral deposition patterns may be attributed to lower initial spray velocity, initial droplet evaporation rate, and possibly initial droplet sizes of Proventil HFA. The small orifice diameter (0.25 mm) of the Proventil HFA actuator produced a softer plume with a smaller impact force, resulting in lower oropharyngeal deposition. Cascade impactor measurements showed similar aerodynamic particle size distribution of the CFC and HFA formulations. We also showed that using spacers in the Proventil HFA resulted in a lower oropharyngeal deposition and higher lung deposition, indicating beneficial effects. Comparison of oropharyngeal deposition and those predicted by artificial throats used in the impactor measurements showed that, in general, the artificial throat predicted a lower deposition.
Subject(s)
Albuterol/administration & dosage , Albuterol/pharmacokinetics , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/pharmacokinetics , Chlorofluorocarbons/administration & dosage , Chlorofluorocarbons/pharmacokinetics , Drug Evaluation, Preclinical/instrumentation , Hydrocarbons, Fluorinated/administration & dosage , Hydrocarbons, Fluorinated/pharmacokinetics , Lung/drug effects , Lung/diagnostic imaging , Models, Anatomic , Nebulizers and Vaporizers , Oropharynx/drug effects , Oropharynx/diagnostic imaging , Technetium/administration & dosage , Technetium/pharmacokinetics , Administration, Inhalation , Adult , Aerosols , Albuterol/chemistry , Bronchodilator Agents/chemistry , Chemistry, Pharmaceutical , Chlorofluorocarbons/chemistry , Drug Evaluation, Preclinical/standards , Humans , Hydrocarbons, Fluorinated/chemistry , Male , Particle Size , Radionuclide Imaging , Technetium/chemistry , Tissue DistributionABSTRACT
Acute methemoglobinemia is a medical emergency that can rapidly become fatal. A substantial number of drugs, including topical preparations, can precipitate this condition. I report a rare example of severe, acute methemoglobinemia caused by oropharyngeal anesthesia with topical benzocaine spray for orogastric intubation. The pathophysiology, diagnosis, and treatment of methemoglobinemia are reviewed briefly.
Subject(s)
Anesthetics, Local/adverse effects , Benzocaine/adverse effects , Methemoglobin/analysis , Acute Disease , Administration, Topical , Adult , Aerosols , Anesthesia, Local/adverse effects , Antidotes/therapeutic use , Cyanosis/chemically induced , Emergencies , Gastric Dilatation/therapy , Humans , Intubation, Gastrointestinal , Leukemia, Myeloid, Acute/complications , Male , Methemoglobin/drug effects , Methylene Blue/therapeutic use , Oropharynx/drug effectsABSTRACT
OBJECTIVE: To determine the influence of selective oropharyngeal decontamination (SOD) on the rate of colonization and infection of the respiratory tract in intensive care patients requiring mechanical ventilation for more than 4 days. A financial assessment was also performed. DESIGN: Randomized, prospective, controlled study using amphotericin B, colistin sulfate (polymyxin E), and tobramycin applied to the oropharynx and systemic cefotaxime prophylaxis. SETTING: Anesthesiology intensive care unit (ICU) of a 1500-bed hospital. PATIENTS: A total of 88 patients admitted as emergencies and intubated within less than 24 h were enrolled. Fifty-eight patients received SOD and 30 patients served as controls. Randomization was in the proportion of 2 : 1 study patients to controls. INTERVENTIONS: Microbiological samples from the oropharynx and other infected sites were taken at the time of admission, then twice a week and after extubation. MEASUREMENTS AND RESULTS: With the use of SOD, colonization was significantly reduced. Furthermore, the infection rate decreased from 77% in the controls to 22% in the study patients. Staphylococcus aureus was the main potential pathogen causing colonization and pneumonia. Number of days in the ICU, duration of ventilation, and mortality were not significantly decreased. The total cost of antibiotics was reduced. Development of resistance was not observed. CONCLUSIONS: The use of SOD significantly reduced the colonization and pneumonia and the total charge for antibiotics. The length of stay in the ICU, duration of ventilation, and mortality were similar. No resistance was observed. Staphylococcus aureus was selected by SOD in some patients and the clinical relevance needs further observation.
Subject(s)
Amphotericin B/therapeutic use , Anti-Bacterial Agents/therapeutic use , Colistin/therapeutic use , Cross Infection/prevention & control , Oropharynx/microbiology , Pneumonia/prevention & control , Tobramycin/therapeutic use , Adult , Cross Infection/mortality , Drug Resistance, Microbial , Female , Humans , Intensive Care Units , Male , Microbial Sensitivity Tests , Middle Aged , Oropharynx/drug effects , Pneumonia/mortality , Respiration, ArtificialABSTRACT
PURPOSE: The purpose of this investigation was to determine the influence on the antimicrobial activity of cetylpyridinium chloride of the various components of the formulation of each of six candy based lozenges. METHODS: In vivo activity was investigated using six volunteers by determining the reduction in colony forming units recoverable from the oropharynx after sucking each lozenge separately on different days. In vitro determinations investigated the relative activity of aqueous solutions of the lozenges, the effect on activity of additional active ingredients, pH and lozenge base ingredients against separate inocula of each of the test organisms Staphylococcus aureus, Streptococcus pyogenes and Candida albicans. RESULTS: Both in vivo and in vitro results showed that the pH of the dissolved lozenge solution was the single most influential readily adjustable formulation parameter which significantly influenced the activity of cetylpyridinium chloride activity in candy based lozenges. CONCLUSIONS: Lozenges containing cetylpyridinium chloride as the active ingredient should be formulated at a pH greater than 5.5.
Subject(s)
Anti-Infective Agents, Local/pharmacology , Candida albicans/drug effects , Cetylpyridinium/pharmacology , Oropharynx/microbiology , Staphylococcus aureus/drug effects , Streptococcus pyogenes/drug effects , Administration, Oral , Anesthetics, Local/pharmacology , Anti-Infective Agents, Local/administration & dosage , Ascorbic Acid/pharmacology , Benzocaine/pharmacology , Benzyl Alcohol , Benzyl Alcohols/pharmacology , Candida albicans/growth & development , Candy , Cetylpyridinium/administration & dosage , Colony Count, Microbial , Dosage Forms/standards , Eucalyptus , Glucose/pharmacology , Humans , Hydrogen-Ion Concentration , Menthol/pharmacology , Oropharynx/drug effects , Plants, Medicinal , Saliva/microbiology , Solubility , Staphylococcus aureus/growth & development , Streptococcus pyogenes/growth & development , Sucrose/pharmacologyABSTRACT
In 20 patients undergoing topical anesthesia for gastroscopic examination, serum concentrations of lidocaine and its metabolite, monomethylglycinexylidide (MEGX), were measured. Patients were divided randomly into two groups: a gel group, in which 5 ml of 2% lidocaine gel was applied to the throat for 20 minutes; and a solution group, in which 40 ml of 2% lidocaine solution was administered by gargling for five minutes. The effect of oropharyngeal anesthesia was comparable in both groups. In the gel group, the serum levels of lidocaine and MEGX were not elevated at 15 minutes after application of the anesthetic. However, in the solution group, a rise in both serum lidocaine and MEGX at 15 minutes after anesthesia was detected in some of the patients (40%). Increased serum MEGX concentrations, which correlated well with serum lidocaine concentrations, were associated with the age of the patient (r = 0.606; p < 0.05), but not with height or weight. As a topical anesthetic for endoscopic examination, we prefer lidocaine gel to lidocaine solution, because the latter might be absorbed more rapidly and unpredictably in some, especially aged patients.
Subject(s)
Anesthesia, Local , Gastroscopy , Lidocaine/analogs & derivatives , Lidocaine/blood , Adult , Age Factors , Female , Gels , Humans , Lidocaine/administration & dosage , Lidocaine/adverse effects , Male , Oropharynx/drug effects , Time FactorsABSTRACT
Based on the theory that obstructive (OSA) and central (CSA) sleep apneas share common pathophysiologic mechanisms, we attempted to treat eight patients with predominantly CSA by continuous positive airway pressure (CPAP). All patients exhibited repetitive episodes of CSA and mixed sleep apneas (MSA) in the supine position with a mean duration of 23.7 +/- 0.7 s and 34.5 +/- 1.3 s, respectively. The pattern of apnea changed when the subject lay in the lateral position. Five patients were observed to develop OSA in the lateral position with a mean duration of 27.2 +/- 1.5 s, while the other three patients snored continuously. High levels of CPAP (range 9.0 to 16.5 cm H2O) prevented all CSA and MSA and resulted in quiet breathing in all eight patients. Intermediate levels of CPAP produced firstly MSA, then purely OSA and/or continuous snoring. Low levels of nasal CPAP also prevented OSA and snoring occurring in the lateral posture in all subjects (range 2.0 to 8.3 cm H2O). Three patients are currently on home CPAP therapy for a range of four to 36 months. We conclude that upper airway collapse in the supine posture has a key role in the induction of CSA. We suggest that a reflex inhibition of respiration through activation of supraglottic mucosal receptors during passive oropharyngeal airway closure caused CSA in these patients.
Subject(s)
Positive-Pressure Respiration , Sleep Apnea Syndromes/therapy , Adult , Aged , Airway Resistance , Anesthesia, Local , Humans , Male , Middle Aged , Oropharynx/drug effects , Posture , Respiratory Function Tests , Sleep Apnea Syndromes/etiology , Sleep Apnea Syndromes/physiopathology , Snoring/physiopathologyABSTRACT
Bleomycin can be administered intravenously, intramuscularly and also locally into the tumor. Bleomycin in oil suspension (BOS) remains longer in the tumor-region with higher levels. In 6 patients with squamous cell carcinomas of the mouth, oropharynx and maxillary sinus, the intratumorous BOS-therapy was performed. The maximum dosage given was 180 mg. The results included: Progression (1), no-response (2), minor response (2), partial remission (1).